Recipharm Appoints Key Account Director
This article was originally published in Scrip
Recipharm has appointed Anke Mollowitz key account director. Mollowitz has more than 13 years' experience in sales and in 2005 she joined Haupt Pharma Wülfing GmbH. At Haupt Pharma Mollowitz worked as sales representatives and project manager and later, she was head of customer service.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.